High Spatial Resolution Detector System Based on Reconfigurable Dual-FPGA Approach for Coincidence Measurements.

Time-resolved spectroscopic and electron-ion coincidence techniques are essential to study dynamic processes in materials or chemical compounds. For this type of analysis, it is necessary to have detectors capable of providing, in addition to image-related information, the time of arrival for each individual detected particle ("x, y, time"). The electronics capable of handling such sensors must meet requirements achievable only with time-to-digital converters (TDC) with a resolution on the order of tens of picoseconds and the use of a field-programmable gate array (FPGA) to manage data acquisition and transmission. This study introduces the design and implementation of an innovative TDC based on two FPGAs working symbiotically with different tasks: the first (AMD/Xilinx Artix® 7) directly implements a TDC, aiming for a temporal precision of 12 picoseconds, while the second (Intel Cyclone® 10) manages the acquisition and connectivity with the external world. The TDC has been optimized to operate on eight channels (+ sync) simultaneously but is potentially extendable to a greater number of channels, making it particularly suitable for coincidence measurements where it is necessary to temporally correlate multiple pieces of information from various measurement systems.

Investigating Acute Hepatitis after SARS-CoV-2 Vaccination or Infection: A Genetic Case Series.

(1) Background: Despite the advantages of COVID-19 vaccination, rare cases of acute hepatitis developing after the administration of the COVID-19 vaccine or the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been reported. The aim of the study is to describe a case series of patients who experienced the onset of acute hepatitis, with or without autoimmune features, following SARS-CoV-2 vaccination or infection and to hypothesize a genetic susceptibility in the pathogenesis. (2) Methods: A group of patients with acute onset hepatitis following SARS-CoV-2 vaccination or infection were evaluated in our hepatology outpatient clinic, where they underwent biochemical and autoimmune tests. Hepatitis A (HAV), B (HBV), and C virus (HCV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), and human immunodeficiency virus (HIV) infections were excluded. Patients with a diagnosis of autoimmune hepatitis (AIH) or drug-induced liver injury (DILI) underwent HLA typing and histological testing. (3) Results: Five patients experienced new-onset AIH after COVID-19 vaccination, one of which developed mild symptoms after vaccination that strongly worsened during subsequent SARS-CoV-2 infection. One patient had AIH relapse after COVID-19 vaccination while on maintenance immunosuppressive treatment. All of them had HLA DRB1 alleles known to confer susceptibility to AIH (HLA DRB1*03,*07,*13,*14), and in three of them, HLA DRB1*11 was also detected. Two patients developed acute hepatitis without autoimmune hallmarks which resolved spontaneously, both positive for HLA DRB1*11. (4) Conclusions: An association between AIH and COVID-19 vaccine or infection can be hypothesized in individuals with a genetic predisposition. In patients without autoimmune features and spontaneous improvement of hypertransaminasemia, the diagnosis of drug-induced liver injury (DILI) is probable. Further studies are needed to determine the presence of an actual association and identify a possible role of HLA DRB1*11 in the pathogenesis of acute liver injury after SARS-CoV2 vaccination or infection.